Skip to main content
TipRanks
Go Ultimate75% OFF

Fuji Pharma Co., Ltd. (4554) AI Stock Analysis

0 Followers
JP:4554

Fuji Pharma Co., Ltd.

(TSE/TYO:4554)

Select Model
Rating:62Neutral
Price Target:JPY 1,999.00â–²(12.94% Upside)
Action:reiterated
Date:11/11/26

The overall score of 62 reflects a company with a solid financial foundation but facing operational headwinds. The primary strength is a significantly improved balance sheet and cash flow generation, which reduces financial risk. The main detractor is declining profitability and margins, which weigh on the financial performance score. Technicals are lackluster, with the stock in a longer-term downtrend, while the valuation is fair, offering some support.

Positive Factors
Steady Revenue GrowthSustained revenue expansion indicates continuing demand for the company’s prescription medicines and supports a durable growth foundation. Re-acceleration after moderation suggests the top-line trajectory remains resilient, providing scope to fund development, commercialization, and other strategic priorities.
Negative Factors
Volatile Net ProfitabilityThe sharp change in net-margin performance shows that revenue growth and operating profit have not translated consistently into bottom-line earnings. This volatility reduces earnings visibility and may limit the reliability of internal funding for development, commercialization, and shareholder returns.

Fuji Pharma Co., Ltd. (4554) vs. iShares MSCI Japan ETF (EWJ)

-10%0%10%20%30%40%50%JP:4554+3.04%EWJ+11.78%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 46.15B
Dividend Yield
2.27%
Average Volume (3M)
125.33K
Price to Earnings (P/E)
15.9
Beta (1Y)
0.79
Revenue Growth
20.72%
EPS Growth
-10.35%
Country
Japan
Employees
1,760
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Fuji Pharma Co., Ltd. Business Overview & Revenue Model

Company Description

Fuji Pharma Co., Ltd. is a pharmaceutical company that operates globally, focusing on the complete spectrum of drug development, from initial research and discovery through manufacturing and commercialization. Its comprehensive product line includes...

Fuji Pharma Co., Ltd. Financial Statement Overview

Summary

Financial performance is mixed. The balance sheet is strong with improving leverage (debt-to-equity 0.41) and cash flow has turned robustly positive (FCF ¥4.1B TTM). However, profitability is declining, with net margin compressing to 4.5% TTM and ROE falling to 5.4%, which tempers the overall score.

Income Statement

58Neutral

Balance Sheet

72Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMSep 2026Sep 2025Sep 2024Sep 2023Sep 2022
Income Statement
Total Revenue62.39B62.39B51.68B46.14B40.89B35.43B
Gross Profit24.32B22.77B19.29B16.51B15.37B13.62B
EBITDA9.47B6.36B8.96B7.56B6.88B6.52B
Net Income2.83B2.83B3.00B6.15B3.44B2.70B
Balance Sheet
Total Assets98.29B98.29B93.63B90.58B86.40B75.97B
Cash, Cash Equivalents and Short-Term Investments9.50B9.50B7.25B4.58B2.32B3.55B
Total Debt28.37B28.37B30.94B29.25B28.95B24.57B
Total Liabilities45.83B45.83B46.72B45.01B45.22B40.17B
Stockholders Equity52.45B52.45B46.91B45.56B41.17B35.80B
Cash Flow
Free Cash Flow04.08B3.82B1.37B-1.41B-5.75B
Operating Cash Flow06.17B5.80B4.15B1.92B-658.00M
Investing Cash Flow0-3.63B-4.22B-1.66B-5.24B-11.27B
Financing Cash Flow0-429.00M954.00M-435.00M1.92B5.09B

Fuji Pharma Co., Ltd. Technical Analysis

Technical Analysis SentimentNegative
Last Price1770.00

Price Trends

50DMA1805.29Negative
100DMA1835.03Negative
200DMA2023.54Negative

Market Momentum

MACD-0.79Positive
RSI43.14Neutral
STOCH22.13Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4554, the sentiment is Negative. The current price of 1770.00 is below the 20-day moving average (MA) of 1839.15, below the 50-day MA of 1805.29, and below the 200-day MA of 2023.54, indicating a bearish trend. The MACD of -0.79 indicates Positive momentum. The RSI at 43.14 is Neutral, neither overbought nor oversold. The STOCH value of 22.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4554.

Fuji Pharma Co., Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4554 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4534JP:453473OutperformJPY 114.51B11.147.68%2.45%15.85%60.55%
JP:4886JP:488669NeutralJPY 56.74B11.43―3.05%―9.04%
JP:4577JP:457767NeutralJPY 37.71B11.98―3.06%-2.83%65.69%
JP:4538JP:453863NeutralJPY 19.04B8.28―4.15%2.29%―
JP:4554JP:455462NeutralJPY 46.15B15.935.56%2.27%20.72%-10.35%
JP:4569JP:456958NeutralJPY 57.90B161.98―4.27%-6.48%-95.83%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%JP:4554JP:4534JP:4538JP:4569JP:4577JP:4886Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4554 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4554Fuji Pharma Co., Ltd.1770.0052.223.04%
JP:4534Mochida Pharmaceutical Co., Ltd.3365.0084.752.58%
JP:4538Fuso Pharmaceutical Industries,Ltd.2170.0060.422.86%
JP:4569KYORIN Pharmaceutical Co.,Ltd.1100.00-335.63-23.38%
JP:4577Daito Pharmaceutical Co., Ltd.1307.0077.986.34%
JP:4886ASKA Pharmaceutical Holdings Co., Ltd.2132.00127.406.36%

Fuji Pharma Co., Ltd. Corporate Events

Fuji Pharma Raises Year-End Dividend to 29 Yen Per Share

Nov 10, 2026

Fuji Pharma’s board resolved on November 10, 2026, to pay a year-end dividend of 29 yen per share for a September 30, 2026 record date, totaling 758 million yen from retained earnings. The dividend’s effective date is December 21, 2026.Fuji Pharma sa...

Fuji Pharma Reports Fiscal 2026 Consolidated Results

Nov 10, 2026

Fuji Pharma Co., Ltd., listed on the Tokyo Stock Exchange under code 4554, released consolidated financial results for the fiscal year ended September 30, 2026. The release reports results under Japanese GAAP for the period from October 1, 2025, thro...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 11, 2026